Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Postow

Showing results (1-10 of 212) with videos related to

Pageof 22
Sort By:
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Managing immune checkpoint-blocking antibody side effectsMichael A Postow
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?Michael A Postow
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
Toxicities of checkpoint inhibitors: causes and managementMichael A Postow
FEBS Letters|October 29, 2013
Checkpoint blocking antibodies in cancer immunotherapyChrisann Kyi, Michael A Postow
Pharmacology & Therapeutics|January 14, 2015
Immune checkpoint modulation: rational design of combination strategiesDmitriy Zamarin, Michael A Postow
Pharmacogenomics and Personalized Medicine|December 9, 2014
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayParisa Momtaz, Michael A Postow
Immunotherapy|June 29, 2016
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challengesChrisann Kyi, Michael A Postow
Cancer|April 30, 2025
Top advances of the year: Neoadjuvant immunotherapy in melanomaMonica F Chen, Michael A Postow
International Journal of Radiation Oncology, Biology, Physics|March 26, 2014
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomesChristopher A Barker, Michael A Postow
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?Jeffrey S Weber, Michael A Postow
Pageof 22

Showing results (1-10 of 212) with videos related to

Sort By:
Pageof 22
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 21, 2015
Managing immune checkpoint-blocking antibody side effectsMichael A Postow
Clinical Advances in Hematology & Oncology : H&O|June 1, 2018
Does adjuvant therapy for high-risk melanoma with either immunotherapy or targeted therapy affect therapeutic choices at relapse?Michael A Postow
Clinical Advances in Hematology & Oncology : H&O|June 13, 2019
Toxicities of checkpoint inhibitors: causes and managementMichael A Postow
FEBS Letters|October 29, 2013
Checkpoint blocking antibodies in cancer immunotherapyChrisann Kyi, Michael A Postow
Pharmacology & Therapeutics|January 14, 2015
Immune checkpoint modulation: rational design of combination strategiesDmitriy Zamarin, Michael A Postow
Pharmacogenomics and Personalized Medicine|December 9, 2014
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathwayParisa Momtaz, Michael A Postow
Immunotherapy|June 29, 2016
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challengesChrisann Kyi, Michael A Postow
Cancer|April 30, 2025
Top advances of the year: Neoadjuvant immunotherapy in melanomaMonica F Chen, Michael A Postow
International Journal of Radiation Oncology, Biology, Physics|March 26, 2014
Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomesChristopher A Barker, Michael A Postow
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2020
TNFα Blockade in Checkpoint Inhibition: The Good, the Bad, or the Ugly?Jeffrey S Weber, Michael A Postow
Pageof 22